

Men's Health & Wellness Test – Cotinine, Creatinine, Ferritin Results

The following pages provide additional information that should be shared with your healthcare professional.

DETAILED PATIENT RESULTS TABLE

Analyte	Quantitative	Qualitative	Reportable Range	Cutoff	Target Range
Blood Cotinine (Nicotine Metabolite)		Negative			Negative
Blood Creatinine	1.0 mg/dL	Negative	0.8 - 10.0 mg/mL	1.4 mg/mL	<1.4 mg/mL
Ferritin	100 ng/mL	Negative	12 - 1500 ng/mL	20 ng/mL	20-400 ng/mL

Men's Health & Wellness Test – Detailed Scientific Validation


imaware™ tests are tested to be highly accurate and precise. The following data can be reviewed by your medical professional to better understand the validity of the imaware test.

BLOOD CREATININE TEST – SCIENTIFIC VALIDATION

Accuracy

Paired serum and dried serum spot samples containing varying concentrations of Creatinine were tested. Creatinine concentrations observed for the dried serum samples versus serum (enzymatic colorimetric method) were statistically analyzed by simple regression:

N=26		
Correlation Coefficient	0.99	
Slope	0.77	
Intercept	0.19	
	DBS Creatinine	Comparable Serum Method
Mean Creatinine	1.5	1.4
Standard Deviation of Range	1.5	1.2




FERRITIN TEST – SCIENTIFIC VALIDATION

Accuracy

Paired serum and dried serum spot samples containing varying concentrations of Ferritin were tested. Ferritin concentrations observed for the dried serum samples versus serum (Enhanced chemiluminescence immunoassay method) were statistically analyzed by simple regression:

N=26		
Correlation Coefficient	0.99	
Slope	1.06	
Intercept	-11.02	
	DBS Ferritin	Comparable Serum Method
Mean Ferritin	1.5	1.4
Standard Deviation of Range	1.5	1.2



Men's Health & Wellness Test – Prostate Cancer Results

The following pages provide additional information that should be shared with your healthcare professional.

DETAILED PATIENT RESULTS TABLE

Analyte	Quantitative	Qualitative	Reportable Range	Cutoff	Target Range
PSA, Total	2.0 ng/mL	Negative	0.5 - 100.0 ng/mL	4.0 ng/mL	<4.0 ng/mL

PATIENT DISEASE AND SYMPTOMS STATUS

- You indicated you have not been previously diagnosed
- You indicated you do not have a family history of prostate cancer
- You indicated you currently do not smoke

Men's Health & Wellness Test – Prostate Cancer Results – Detailed Scientific Validation


imaware™ tests are tested to be highly accurate and precise. The following data can be reviewed by your medical professional to better understand the validity of the imaware test.

TOTAL PSA TEST – SCIENTIFIC VALIDATION

Accuracy

Paired serum and dried serum spot samples containing varying concentrations of total PSA were tested. PSA concentrations observed for the dried serum samples versus serum (Electrochemilumiscence-based assay) were statistically analyzed by simple regression:

N=27		
Correlation Coefficient	0.9964	
Slope	1.02	
Intercept	-0.23	
	DBS PSA	Comparable Serum Method
Mean Prostate Specific Antigen	3.04	3.19
Standard Deviation of Range	2.94	2.86



Men's Health & Wellness Test – Testosterone Results

The following pages provide additional information that should be shared with your healthcare professional.

DETAILED PATIENT RESULTS TABLE

Analyte	Quantitative	Qualitative	Reportable Range	Cutoff	Target Range
Testosterone, Total	400 ng/dL	Normal	130 - 1500 ng/mL	240 ng/mL	240 - 950 ng/mL

PATIENT DISEASE AND SYMPTOMS STATUS

- You indicated you have not been previously tested
- You indicated you do not have a family history of this condition
- You indicated you currently do not smoke

Men's Health & Wellness Test – Testosterone Results – Detailed Scientific Validation


imaware™ tests are tested to be highly accurate and precise. The following data can be reviewed by your medical professional to better understand the validity of the imaware test.

TOTAL TESTOSTERONE TEST – SCIENTIFIC VALIDATION

Accuracy

Paired serum and dried serum spot samples containing varying concentrations of Testosterone were tested. Testosterone concentrations observed for the dried serum samples versus serum (Enhanced chemiluminescence immunoassay method) were statistically analyzed by simple regression:

N=35		
Correlation Coefficient	0.89	
Slope	0.77	
Intercept	24.7	
	DSS Testosterone	Comparable Serum Method
Mean Testosterone	379.8	462.3
Standard Deviation of Range	137.7	166.1



Men's Health & Wellness Test – Additional Information

SCIENTIFIC REFERENCES

1. Courtney Nagel Sandler, MDMarie E. McDonnell, MD
2016 May, The role of hemoglobin A1c in the assessment of diabetes and cardiovascular risk
Cleveland Clinic Journal of Medicine ; 83 Suppl 1(5):S4-S10
2. Ivana R Sequeira, Sally D Poppitt1
2017, HbA1c as a marker of prediabetes: A reliable screening tool or not,
Review Article – Insights in Nutrition and Metabolism () Volume 1, Issue 1
3. Ike S. Okosun, J. Paul Seale, Rodney Lyn and Y. Monique Davis-Smith.
20 November 2015, Improving Detection of Prediabetes in Children and Adults: Using Combinations of Blood Glucose Tests.
Frontier, Public Health, <https://doi.org/10.3389/fpubh.2015.00260>;
4. Ho-Pham LT, Nguyen UDT, Tran TX, Nguyen TV.
August 17, 2017, Discordance in the diagnosis of diabetes: comparison between HbA1c and fasting plasma
PLOS ONE. doi:10.1371/journal.pone.0182192
5. Simmons RK, Rahman M, Jakes RW, et al.
2011, Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort.
Diabetologia.; 54(2): 312-319.
6. Couderc R1, Antar M1, Bonnefont-Rousselot D2, Paul JL3, Therond P4.
Couderc R, et al. Ann Biol Clin (Paris). 2017.
Blood lipid tests in 2017. Review article
7. Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services Task Force.
Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Jeanne TL Ann Intern Med.
2016;165(8):560.
8. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.
Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB,
Vasan RS. JAMA. 2007;298(7):776.
9. Lipid parameters for measuring risk of cardiovascular disease.
Arsenault BJ, Boekholdt SM, Kastelein JJ; Nat Rev Cardiol. 2011 Apr;8(4):197-206.
Epub 2011 Feb 01.
10. Clinical Utility of a Fingertick Technology to Identify Individuals With Abnormal Blood Lipids and
High-Sensitivity C-Reactive Protein Levels
Parin Parikh, MD, Heidi Mochari, MPH, RD, and Lori Mosca, MD, MPH, PhD; Am J Health Promot. 2009 Mar-Apr; 23(4): 279-282.
doi: 10.4278/ajhp.071221140
11. Monitoring vitamin D status and intake in the US population: essential to understanding the role of vitamin D in health
Mona S Calvo; The American Journal of Clinical Nutrition, Volume 110, Issue 1, July 2019, Pages 6-7, <https://doi.org/10.1093/ajcn/nqz069>
12. Manson JE, Brannon PM, Rosen CJ, Taylor CL. Vitamin D Deficiency – Is There Really a Pandemic?
N Engl J Med 2016; 375:1817.
13. Forrest KY, Stuhldreher WL. Prevalence and correlates of vitamin D deficiency in US adults.
Nutr Res 2011; 31:48.
14. Yetley EA. Assessing the vitamin D status of the US population.
Am J Clin Nutr 2008; 88:558S.
15. Miller W, Myers G, Ashwood E, et al. Creatinine measurement: state of the art in accuracy and interlaboratory harmonization.
Arch Pathol Lab Med. 2005;129(3):297-304
16. Silva AC1, Gómez JF2, Lugon JRI, Graciano ML1.
Bras Nefrol.2016 Mar;38(1):15-21. doi: 10.5935/0101-2800.20160004.
Creatinine measurement on dry blood spot sample for chronic kidney disease screening.

Men's Health & Wellness Test – Additional Information Continued

SCIENTIFIC REFERENCES

17. AABB Ad Hoc Iron-Deficiency Working Group. AABB donor iron deficiency risk-based decision-making assessment report; 2018 [cited 2019 March 11]. Available from: <https://www.aabb.org/tm/Documents/AABB-Donor-Iron-Deficiency-RBDM-Assessment-Report.pdf>
18. Alpert PF; Urology.2018 Aug;118:119-126. doi: 10.1016/j.urology.2018.02.049. Epub 2018 May 14. New Evidence for the Benefit of Prostate-specific Antigen Screening: Data From 400,887 Kaiser Permanente Patients.
19. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. *Cancer Causes Control* 2008; 19:175..
20. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Schröder FH, Hugosson J, Carlsson S, Tammela T, Määttänen L, Auvinen A, Kwiatkowski M, Recker F, Roobol MJ; *Eur Urol*. 2012;62(5):745. Epub 2012 Jun 7.
21. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials; *Ann Intern Med*. 2017;167(7):449-455. Published at www.annals.org on 5 September 2017; DOI: 10.7326/M16-2586
22. Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A. Serum testosterone levels in male hypogonadism: Why and when to check-A review. *Int J Clin Pract*. 2017;71(11):e12995. doi:10.1111/ijcp.1299
23. Should Family Physicians Screen for Testosterone Deficiency in Men? Yes: Screening Joel J. Heidelbaugh, MD, University of Michigan Medical School, Ann Arbor, Michigan; *Am Fam Physician*. 2015 Feb 15;91(4):220-221.
24. McBride JA, Carson CC 3rd, Coward RM. Testosterone deficiency in the aging male. *Ther Adv Urol*. 2016;8(1):47-60. doi:10.1177/175628721561296
25. Crawford ED1, Barqawi AB, O'Donnell C, Morgentaler A.; The association of time of day and serum testosterone concentration in a large screening population. *BJU Int*.2007 Sep;100(3):509-13. Epub 2007 Jun 6.

PERFORMING LABORATORY INFORMATION

- Patient Sample was performed on July 5, 2019 by CoreMedica Labs.
- CLIA Number 26D2013888 CAP Accreditation 7537862
- Lab Location: 200 NE Missouri, Ste 302, Lees Summit, MO, 64081
- Lab Director: Dr. Cristian Saez, Ph.D.

TEST NOTES AND LIMITATIONS

- These test results should be shared with your healthcare provider
- This test is not to diagnose any health condition - only your healthcare provider can make that determination, in light of your overall health history and the results of other testing they may decide to order
- Please consult your healthcare provider before making any dietary changes